KR900017609A - 안정화된 칼시토닌 약학 조성물 - Google Patents

안정화된 칼시토닌 약학 조성물 Download PDF

Info

Publication number
KR900017609A
KR900017609A KR1019900007438A KR900007438A KR900017609A KR 900017609 A KR900017609 A KR 900017609A KR 1019900007438 A KR1019900007438 A KR 1019900007438A KR 900007438 A KR900007438 A KR 900007438A KR 900017609 A KR900017609 A KR 900017609A
Authority
KR
South Korea
Prior art keywords
calcitonin
pharmaceutical composition
solid
ethylenediamine tetraacetate
calcitonin pharmaceutical
Prior art date
Application number
KR1019900007438A
Other languages
English (en)
Other versions
KR950004697B1 (ko
Inventor
히데끼 고바야시
세이지 모찌즈끼
유지 마끼노
요시끼 스즈끼
Original Assignee
이따가끼 히로시
데이진 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이따가끼 히로시, 데이진 가부시끼가이샤 filed Critical 이따가끼 히로시
Publication of KR900017609A publication Critical patent/KR900017609A/ko
Application granted granted Critical
Publication of KR950004697B1 publication Critical patent/KR950004697B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

안정화된 칼시토닌 약학 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 칼시토닌 및 에틸렌디아민 테트라아세테이트를 함유한 수용액을 동결 건조시킴으로써 또는 칼시토닌 및 에틸렌 디아민 테트라아세테이트를 함유하는 수용액에 빈용매(poor solvent)를 가함으로써 수득되는, 치료적으로 유효한 양의 하나 이상의 칼시토닌 및 하나이상의 에틸렌디아민 테트라아세테이트를 함유하는 고체 칼시토닌 약학 조성물.
  2. 제1항에 있어서, 에틸렌디아민 테트라아세테이트가 디소듐 에틸렌디아민 테트라아세테이트인 고체 칼시토닌 약학 조성물.
  3. 제1항에 있어서, 에틸렌디아민 테트라아세테이트의 양이 칼시토닌 1IU당 0.005내지 50㎍인 고체 칼시토닌 약학 조성물.
  4. 제1항에 있어서, 비강투여제제의 형태인 고체 칼시토닌 약학 조성물.
  5. 제4항에 있어서, 비강투여제제의 형태가 경질 젤라틴 캡슐(hard gelatin capsule)인 고체 칼시토닌 약학 조성물.
  6. 제1항에 있어서, 주사제 또는 점안투여용의 형태인 고체 칼시토닌 약학 조성물.
    ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019900007438A 1989-05-23 1990-05-23 안정화된 칼시토닌 약학 조성물 KR950004697B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1-127743 1989-05-23
JP1127743A JP2514249B2 (ja) 1989-05-23 1989-05-23 安定化されたカルシトニン類医薬組成物

Publications (2)

Publication Number Publication Date
KR900017609A true KR900017609A (ko) 1990-12-19
KR950004697B1 KR950004697B1 (ko) 1995-05-04

Family

ID=14967589

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900007438A KR950004697B1 (ko) 1989-05-23 1990-05-23 안정화된 칼시토닌 약학 조성물

Country Status (10)

Country Link
US (1) US5211950A (ko)
EP (1) EP0399781B1 (ko)
JP (1) JP2514249B2 (ko)
KR (1) KR950004697B1 (ko)
AT (1) ATE83667T1 (ko)
AU (1) AU635740B2 (ko)
CA (1) CA2017285C (ko)
DE (1) DE69000640T2 (ko)
DK (1) DK0399781T3 (ko)
ES (1) ES2053109T3 (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0489217A1 (en) * 1990-12-05 1992-06-10 Dr. A. Tosi Farmaceutici S.R.L. Calcitonin compositions for intranasal administration
JP3179538B2 (ja) * 1990-12-11 2001-06-25 ノバルティス アクチエンゲゼルシャフト 安定なヒトカルシトニンの水性溶液
IT1244500B (it) * 1991-03-21 1994-07-15 Pulitzer Italiana Impiego di sali minerali di trometamina in composizioni farmaceutiche a base di calcitonina somministrabili per via rettale in terapia umana
US5571788A (en) * 1991-12-09 1996-11-05 Ciba-Geigy Corporation Stable calcitonin pharmaceutical compositions
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
GB9623205D0 (en) 1996-11-07 1997-01-08 Eurand Int Novel pharmaceutical compositions
CA2288968A1 (en) 1997-04-14 1998-10-22 Takashi Yazaki Permucous preparation
US7402559B2 (en) * 1999-03-24 2008-07-22 Msh Pharma, Incorporated Composition and method of treatment for urogenital conditions
ES2256035T3 (es) 1999-09-17 2006-07-16 Daiichi Asubio Pharma Co., Ltd. Composiciones farmaceuticas que comprenden faropenem sodico y una diamina acetato para mejorar la absorcion gastrointestinal.
US7812120B2 (en) * 2003-03-21 2010-10-12 Par Pharmaceutical, Inc. Nasal calcitonin formulations containing chlorobutanol
AU2003901515A0 (en) * 2003-04-02 2003-04-17 Norika Holdings Sterilisation process for pharmaceutical product
US7648965B2 (en) * 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US9511144B2 (en) 2013-03-14 2016-12-06 The Proctor & Gamble Company Cosmetic compositions and methods providing enhanced penetration of skin care actives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2364659A1 (fr) * 1976-09-21 1978-04-14 Commissariat Energie Atomique Medicament antagoniste de l'action de la gastrine et des polypeptides apparentes
US4241051A (en) * 1977-11-04 1980-12-23 Christie Robert B Calcitonin
US4476116A (en) * 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
AU572815B2 (en) * 1982-12-29 1988-05-19 Armour Pharmaceutical Company Pharmaceutical calcitonin compositions for intranasal application
US4663309A (en) * 1983-06-29 1987-05-05 University Patents, Inc. Novel peptide hormones with calcitonin-like activity
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
IT1204400B (it) * 1986-06-20 1989-03-01 Sclavo Spa Composizioni farmaceutiche contenente una calcitonina
IT1222734B (it) * 1987-09-25 1990-09-12 Scalvo S P A Formulaziopne farmaceutiche e forme di dosaggio per la somminaistarzione rettale di calcitonina

Also Published As

Publication number Publication date
JP2514249B2 (ja) 1996-07-10
AU5580290A (en) 1990-11-29
CA2017285C (en) 1996-12-10
DE69000640T2 (de) 1993-04-22
DE69000640D1 (de) 1993-02-04
ATE83667T1 (de) 1993-01-15
DK0399781T3 (da) 1993-02-01
KR950004697B1 (ko) 1995-05-04
EP0399781B1 (en) 1992-12-23
US5211950A (en) 1993-05-18
JPH02306921A (ja) 1990-12-20
AU635740B2 (en) 1993-04-01
EP0399781A1 (en) 1990-11-28
ES2053109T3 (es) 1994-07-16
CA2017285A1 (en) 1990-11-23

Similar Documents

Publication Publication Date Title
KR900017609A (ko) 안정화된 칼시토닌 약학 조성물
ES2136662T3 (es) Formas de presentacion farmaceuticas y de otro tipo.
ATE189228T1 (de) Peptide mit zyklischen hauptketten, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
ES2150496T3 (es) Cicloalquilimidazopiridinas condensadas.
SE8505112D0 (sv) Novel pharmacological compounds
DE3582468D1 (de) Stabilisierte injektionsloesungen von piroxicam.
SE7901683L (sv) Nya resorberbara galeniska kompositioner
DE69521693D1 (de) Taxanderivate enthaltende arzneizubereitungen
FR2636948A1 (fr) N-(2-piperidylmethyl)benzamides substitues anti-arythmiques et composition pharmaceutique les contenant
SE8404065D0 (sv) Novel biologically active compounds
KR910005876A (ko) 모세혈관 취약증의 치료를 위한 극소용 약학적 조성물
ATE65401T1 (de) Stabile, injizierbare loesungen von salzen von vincristin.
KR910021361A (ko) 항궤양 물질
ATE65395T1 (de) Acetylcystein enthaltendes, festes, wasserloeslisches arzneimittel.
FR2536751B1 (fr) Nouveaux derives de tricyclophosphazenes, procede pour leur preparation et leur application en tant que medicament
KR910009270A (ko) 15-케토-프로스타글란딘 화합물을 이용한 심기능장애의 치료방법
KR870007699A (ko) 약용과 화장용으로 대표적으로 사용되는 제제형의 즉석제조용 조성물
UA26442C2 (uk) Фармкомпозиція для профілактики і лікуваhhя захворюваhь, пов'язаhих з порушеhhям обміhу речовиh
KR910016734A (ko) 광학활성 알킬렌디옥시벤젠 유도체 및 치료에의 용도
DE68901656D1 (de) Pharmazeutische zusammensetzung zur milderung der nebenwirkungen von platinhaltigen arzneimitteln.
KR880000094A (ko) 위염치료제
FR2592049B1 (fr) Nouveaux analogues de composes polypeptidiques hypocalcemiants epargnant le calcium de l'organisme, leur preparation et les medicaments contenant ces principes actifs
SE9004169D0 (sv) Anvaendning av farmaceutiska och kosmetiska kompositioner, innehaallande 1,8-dihydroxi-10-fenyl-9-antron som verksam bestaandsdel
SE8206728D0 (sv) Lekemedelspreparat
KR890001549A (ko) 위염 치료제

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

G160 Decision to publish patent application
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080502

Year of fee payment: 14

LAPS Lapse due to unpaid annual fee